Does minimal residual disease (MRD) predict relapse in children with advance B-NHL treated with chemoimmunotherapy: a children's oncology report

被引：0
|
作者：
Shiramizu, B. [1 ]
Goldman, S. [2 ]
Smith, L. [3 ]
Harrison, L. [4 ]
Van de Ven, C. [4 ]
Gross, T. [5 ]
Sanger, W. [6 ]
Perkins, S. [7 ]
Cairo, M. [4 ,8 ,9 ,10 ,11 ]
机构：
[1] Univ Hawaii, Honolulu, HI 96822 USA
[2] Med City Childrens Hosp, Dallas, TX USA
[3] Childrens Oncol Grp, Ctr Data, Omaha, NE USA
[4] New York Med Coll, Dept Pediat, Valhalla, NY 10595 USA
[5] Ohio State Univ, Nationwide Childrens Hosp, Columbus, OH 43210 USA
[6] Univ Nebraska, Omaha, NE 68182 USA
[7] Univ Utah, Salt Lake City, UT USA
[8] New York Med Coll, Dept Med, Valhalla, NY 10595 USA
[9] New York Med Coll, Dept Pathol, Valhalla, NY 10595 USA
[10] New York Med Coll, Dept Microbiol & Immunol, Valhalla, NY 10595 USA
[11] New York Med Coll, Dept Cell Biol & Anat, Valhalla, NY 10595 USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2012年 / 159卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
101
引用
收藏
页码：53 / 53
页数：1
相关论文
共 50 条
  • [31] Prognostic impact of minimal residual disease at the end of consolidation in NCI standard-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group
    Rau, Rachel E.
    Dai, Yunfeng
    Devidas, Meenakshi
    Rabin, Karen R.
    Zweidler-McKay, Patrick
    Angiolillo, Anne
    Schore, Reuven J.
    Burke, Michael J.
    Salzer, Wanda L.
    Heerema, Nyla A.
    Carroll, Andrew J.
    Winick, Naomi J.
    Hunger, Stephen P.
    Raetz, Elizabeth A.
    Loh, Mignon L.
    Wood, Brent L.
    Borowitz, Michael J.
    PEDIATRIC BLOOD & CANCER, 2021, 68 (04)
  • [32] Assessment of end induction minimal residual disease (MRD) in childhood B precursor acute lymphoblastic leukemia (ALL) to eliminate the need for day 14 marrow examination: A Children's Oncology Group study
    Borowitz, Michael J.
    Wood, Brent L.
    Devidas, Meenakshi
    Loh, Mignon L.
    Raetz, Elizabeth A.
    Larsen, Eric
    Maloney, Kelly W.
    Carroll, Andrew J.
    Friedmann, Alison M.
    Gastier-Foster, Julie M.
    Heerema, Nyla A.
    Mattano, Leonard A.
    Nachman, James B.
    Winick, Naomi Joan
    Carroll, William L.
    Hunger, Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [33] Presence of Residual Disease Detected by Multidimensional Flow Cytometry Identifies Patients with AML At High Risk of Relapse - a Report From the Children's Oncology Group
    Loken, Michael R.
    Alonzo, Todd A.
    Pardo, Laura
    Gerbing, Robert B.
    Aplenc, Richard
    Sung, Lillian
    Raimondi, Susana C.
    Hirsch, Betsy A.
    Kahwash, Samir
    Heerema-McKenney, Amy
    Winter, Laura
    Glick, Kathleen
    Byron, Patti
    Fransisco, Laura
    Wallas, Tanya
    Davies, Stella M.
    Smith, Franklin O.
    Gamis, Alan S.
    Meshinchi, Soheil
    BLOOD, 2011, 118 (21) : 1513 - 1513
  • [34] Outcome of advanced stage (III/IV) intermediate-risk patients with mature B-NHL using rituximab plus FAB group B4 chemotherapy: a Children's Oncology Group report
    Goldman, S.
    Smith, L.
    Anderson, J. R.
    Perkins, S.
    Harrison, L.
    Shiramizu, B.
    Sanger, W.
    Barth, M.
    Cairo, M. S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 159 : 24 - 24
  • [35] Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children's Oncology Group study
    Wood, Brent L.
    Devidas, Meenakshi
    Summers, Ryan J.
    Chen, Zhiguo
    Asselin, Barbara
    Rabin, Karen R.
    Zweidler-McKay, Patrick A.
    Winick, Naomi J.
    Borowitz, Michael J.
    Carroll, William L.
    Raetz, Elizabeth A.
    Loh, Mignon L.
    Hunger, Stephen P.
    Dunsmore, Kimberly P.
    Teachey, David T.
    Winter, Stuart S.
    BLOOD, 2023, 142 (24) : 2069 - 2078
  • [36] Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: Implications for residual disease detection: A report from the children's oncology group
    Borowitz, MJ
    Pullen, DJ
    Winick, N
    Martin, PL
    Bowman, WP
    Camitta, B
    CYTOMETRY PART B-CLINICAL CYTOMETRY, 2005, 68B (01) : 18 - 24
  • [37] EXCELLENT OUTCOME IN CNS-POSITIVE PEDIATRIC BURKITT LYMPHOMA AND OTHER MATURE B-NHL TREATED WITH COMBINED CHEMO-IMMUNOTHERAPY (RITUXIMAB plus FAB GROUP C) WITHOUT CNS RADIATION: A CHILDREN'S ONCOLOGY GROUP REPORT
    Frazer, J. K.
    Goldman, S.
    Harrison, L.
    Perkins, S. L.
    Cairo, M. S.
    ANNALS OF ONCOLOGY, 2011, 22 : 177 - 177
  • [38] THE EFFICACY OF RASBURICASE DURING REDUCTION COP CHEMOTHERAPY FOR THE PREVENTION OF TUMOR LYSIS SYNDROME (TLS) IN CHILDREN AND ADOLESCENTS WITH NEWLY DIAGNOSED STAGE III/IV, BM+ AND CNS+ MATURE B-NHL: A CHILDREN'S ONCOLOGY GROUP REPORT
    Hochberg, Jessica
    Galardy, Paul
    Goldman, Stanton
    Smith, Lynette
    Cairo, Mitchell
    PEDIATRIC BLOOD & CANCER, 2012, 58 (07) : 1041 - 1041
  • [39] Identification of Post-Induction Minimal Residual Disease by Multidimensional Flow Cytometry Identifies Patients with AML at High Risk of Relapse and Poor Outcome- a Report From the Children's Oncology Group.
    Meshinchi, Soheil
    Alonzo, Todd A.
    Gerbing, Robert B.
    Ho, Phoenix A.
    Gamis, Alan S.
    Raimondi, Susana C.
    Hirsch, Betsy A.
    Cooper, Todd
    Franklin, Janet
    Pardo, Laura
    Loken, Michael R.
    BLOOD, 2010, 116 (21) : 713 - 713
  • [40] Correlation of end-induction minimal residual disease(MRD) in childhood acute lymphoblastic leukemia (ALL) with clinical and biological risk factors. A children's oncology group study.
    Borowitz, MJ
    Shuster, J
    Viswanatha, DS
    Willman, CS
    Montgomery, K
    Pullen, J
    Carroll, AJ
    Camitta, B
    BLOOD, 2001, 98 (11) : 841A - 841A
12345